Global Bile Duct Cancer Drug Market Overview –
A new report on the global bile duct cancer drugs market has been published by Vision gain. The report extends all the way out to 2031. Analysis of the Leading Regional and Leading National Markets, as well as Profiles of Key Players in the Bile Duct Cancer Drugs Market ADDITIONALLY, the COVID-19 Recovery Scenarios
Because of factors such as the increasing incidence and prevalence rate of bile duct cancer patients around the world, technological advancements in drug development, and increased spending on healthcare, the market for drugs used to treat bile duct cancer has been expanding significantly. In addition, the rising investment in research and development for the purpose of developing novel drugs and therapies is fueling the expansion of the market.
The expansion of the global market for drugs to treat bile duct cancer will be helped along by the adoption of consistent government policies. However, the high cost of bile duct cancer drugs and the rare side effects associated with the drugs and treatment will act as a barrier to the market’s expansion, preventing the market from expanding to its full potential.
Market Dynamics –
The primary factor that will drive expansion of the target market over the course of the forthcoming time period is the rising prevalence and incidences of cancer all over the world. Cancer is the second leading cause of death worldwide, according to the World Health Organization, and it is estimated that approximately 9.5 million people will die from the disease in 2018.
In addition, a growing awareness about cancer prevention and control, higher healthcare expenditures, funding from government and private organization’s, and the rapidly introduction of new technologically advanced medical products and devices are some of the other factors that are expected to drive the growth of the bile duct cancer drug across the globe. On the other hand, expansion of the target market is likely to be hampered to some
degree by the stringent approval requirements imposed by health regulators.
COVID-19 Impact –
Before the COVID-19 pandemic, the global market for drugs to treat cancer of the bile duct was expanding at a significant rate. However, the unexpected outbreak has been shaking up economies all over the world since January 2020. In the beginning, the COVID-19 appeared in the city of Wuhan in China in the month of December 2019. Within a short period of time, the epidemic developed into a pandemic and spread all over the world, with positive cases increasing. According to worldometers, more than 43.5 cases of COVID-19 have been registered across the globe till the 26th of October 2020, with over 1.1 million people losing their lives to the disease.
Competitive Landscape –
The report from Visiongain covers the comprehensive competitive landscape in great detail. This includes an overview of the key players operating in the market, extensive product portfolios, and recent developments, among other things. Accord Healthcare Inc., Bristol-Myers Squibb Company, Celgene Corporation, Delcath Systems Inc., Eli Lilly and Company, F. Hoffman-La Roche AG, Fresenius Kabi AG, Intercept Pharmaceuticals, Inc., Pfizer, Inc., and Teva Pharmaceuticals Industries Ltd are some of the key players that contribute to the global bile duct cancer drug market. Other key players include Pfizer, Inc., and Teva Pharmaceuticals Industries Ltd.
The competitors in the global market for drugs to treat bile duct cancer employ a variety of strategies in order to capitalise on the opportunities currently on offer. For instance, key strategies utilised by market participants include regulatory approvals, mergers and acquisitions, partnerships and collaborations, new product launches, and new product development, amongst others. The Committee for Medicinal Products (CHMP) provided Roche with a favourable opinion on September 18th, 2020, regarding the use of Tecentriq in conjunction with Avastin for the treatment of patients suffering from the most common form of liver cancer.
Key Players –
Johnson & Johnson Private Limited (US)
Mylan N.V. (US)
Teva Pharmaceutical Industries Ltd.(Jerusalem)
Sanofi (France)
Pfizer Inc. (US)
GlaxoSmithKline plc (UK)
AbbVie Inc. (US)
Novartis AG (Switzerland)
Fresenius Kabi AG (Germany)
Eli Lilly and Company (US)
F. Hoffmann-La Roche Ltd. (Switzerland)
Intercept Pharmaceuticals (US)
Kyowa Kirin Co., Ltd. (Japan)
Delcath Systems, Inc. (US)
Accord Healthcare (US)
CONMED Corporation (US)
Boston Scientific Corporation (US)
Bayer AG (Germany)
Bristol-Myers Squibb Company (US)
Merck & Co., Inc. (US)
By Type –
5-fluorouracil (5-FU)
Gemcitabine
Cisplatin
Capecitabine
Oxaliplatin
Others
By Applications –
Hospitals
Clinics
Others
By Region –
North America
The U.S.
Europe
UK
France
Germany
Asia Pacific
China
Japan
India
Latin America
Brazil
Middle East and Africa
